Učitavanje...
Cost–utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels
BACKGROUND: Adjuvant zoledronic acid (za) appears to improve disease-free survival (dfs) in women with early-stage breast cancer and low levels of estrogen (lle) because of induced or natural menopause. Characterizing the cost–utility (cu) of this therapy could help to determine its role in clinical...
Spremljeno u:
| Izdano u: | Curr Oncol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Multimed Inc.
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4530821/ https://ncbi.nlm.nih.gov/pubmed/26300674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2383 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|